Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer



Status:Recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/25/2019
Start Date:August 10, 2017
End Date:September 2022
Contact:Clinical Trials Information Program
Email:cip@vanderbilt.edu
Phone:800-811-8480

Use our guide to learn which trials are right for you!

A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)

This is an open-label, multi-institution, phase Ib trial that evaluates the safety and
tolerability and preliminary anti-tumor activity of fulvestrant, palbociclib and erdafitinib
in patients with ER+/HER2-/FGFR-amplified metastatic breast cancer.

Primary Objectives

• To determine the safety and tolerability of fulvestrant, palbociclib and erdafitinib in
patients with ER+/HER2-/FGFR-amplified MBC.

Secondary Objectives

- To determine the anti-tumor effect of fulvestrant, palbociclib and erdafitinib in
patients with ER+/HER2-/FGFR-amplified MBC.

- Pharmacokinetic assessments of erdafitinib

Correlative Objectives

- To determine the therapeutic predictive role of FGFR1-4, CCND1-2, CDK4 and CDK6
amplifications, and RB1 and ESR1 mutations on clinical outcome

- To determine if the FGFR1 amplification levels is an early surrogate of response

- To determine if the cfDNA results at disease progression show new genomic alterations
potentially associated with resistance to CDK4/6 and FGFR inhibition

- To determine pharmacodynamic biomarkers of FGFR inhibition

Inclusion Criteria:

- Patients must be able to swallow and retain oral medication

- Patients must be ≥ 18 years of age

- Female patients of no childbearing potential must be post-menopausal. Postmenopausal
female subjects should be defined prior to protocol enrollment by any of the
following:

- Participants at least 60 years of age; OR

- Participants under 60 years of age and naturally (spontaneous, no alternative
pathologic or physiological cause) amenorrhea for at least 12 months; OR

- Medical ovarian failure confirmed by follicle-stimulating hormone (FSH) and
estradiol levels in the post menopausal range per local institutional normal
range; OR

- Prior bilateral oophorectomy; OR

- Prior radiation castration with amenorrhea for at least 6 months; OR

- Treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist (such as
goserelin acetate or leuprolide acetate) is permitted for induction of ovarian
suppression as long as it has been initiated at least 28 days prior to study
enrollment

- Patients must have ECOG performance status 0 - 1

- Patients must have clinical stage IV or inoperable locoregional recurrent invasive
mammary carcinoma that is:

- ER+ and/or PgR+ (≥ 1% positive stained cells) by immunohistochemistry (IHC)

- HER2-negative (by IHC or FISH, per ASCO guidelines)

- FGFR1 - 4 amplified

- Patients must have evaluable (may have either measurable or non-measurable)
disease

- Patients must have available tissue for FGFR determination

- Patients must have had at least one line of therapy in the metastatic setting

- Current use of any of the drugs listed on the Cautionary Concomitant Med list has to
be approved by the Study Chair

- Patients must have adequate hematologic, hepatic and renal function. All laboratory
tests must be obtained within 2 weeks from study drug initiation. These include:

- ANC ≥ 1,500/mm3

- Platelet count ≥ 100,000/mm3

- HgB ≥ 9.0 g/dL

- Creatinine clearance ≥ 40 mL/min/1.73 m2

- SGOT, SGPT ≤ 2.5 x ULN if no liver metastasis present; SGOT, SGPT ≤ 4 x ULN if
liver metastasis present

- Albumin ≥ 2.0 g/dL

- Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN if
known Gilbert's syndrome)

- Potassium within institutional normal limits

- Phosphorus ≤ institutional upper limit of normal

Exclusion Criteria:

- Prior use of an FGFR inhibitor

- More than 2 lines of chemotherapy in the metastatic setting. No limit on endocrine
therapy lines. Prior exposure to CDK4/6 inhibitor acceptable.

- Radiation therapy ≤ 2 weeks prior to study entry. Patients who have received prior
radiotherapy must have recovered from toxicity (≤ grade 1) induced by this treatment
(except for alopecia)

- Prior cancer therapy (except for endocrine therapy) must have been discontinued for 1
week prior to initiation of study drugs

- Concurrent anti-cancer therapy other than the ones specified in the protocol is not
permitted during study participation. Bisphosphonates or denosumab are allowed

- Major surgery within 4 weeks of enrollment

- Herbal preparations are not allowed throughout the study, and should be discontinued
14 days prior to initiation of study treatment

- Any corneal or retinal abnormality likely to increase the risk of eye toxicity, such
as:

- Current corneal pathology such as keratitis, keratoconjunctivitis, keratopathy,
corneal abrasion, inflammation or ulceration

- Uncontrolled glaucoma despite standard of care therapy

- Diabetic retinopathy with macular edema

- Known active wet, age-related macular degeneration (AMD)

- Known central serous retinopathy (CSR) or retinal vascular occlusion (RVO)

- Uncontrolled intercurrent illness including, but not limited to:

- Malabsorption syndrome significantly affecting gastrointestinal function

- Ongoing or active infection requiring antibiotics/antivirals

- Impairment of lung function (COPD > grade 2, lung conditions requiring oxygen
therapy)

- Symptomatic congestive heart failure

- Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within
6 months

- Clinically significant cardiac arrhythmia (multifocal premature ventricular
contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or
requires treatment [National Cancer Institute -Common Terminology Criteria for
Adverse Events, Version 4.03, grade 3]

- QTcF ≥ 480 msec on screening EKG

- Known history of clinically significant QT/QTc prolongation or Torsades de
Pointes(TdP)

- ST depression or elevation of ≥ 1.5 mm in 2 or more leads

- Diarrhea of any cause ≥ CTCAE grade 2 that does not resolve within a few days
when adequately treated with anti-diarrhea medications

- Psychiatric illness/social situations that would compromise patient safety or
limit compliance with study requirements including maintenance of a
compliance/pill diary

- Symptomatic brain metastases (patients with a history of brain metastases must be
clinically stable for more than 4 weeks from completion of radiation treatment
and be off steroids)

- Known history of chronic liver or chronic renal failure

- Poor wound healing capacity
We found this trial at
6
sites
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Principal Investigator: Ingrid Mayer, MD
Phone: 800-811-8480
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
New York, New York 10065
?
mi
from
New York, NY
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
550 16th Street
San Francisco, California 94158
?
mi
from
San Francisco, CA
Click here to add this to my saved trials